TERRASCEND CORP (TSND.CA) Stock Fundamental Analysis
Canada - TSX:TSND - CA88105E1088 - Common Stock
1.25 CAD
+0.1 (+8.7%)
Taking everything into account, TSND scores 3 out of 10 in our fundamental rating. TSND was compared to 32 industry peers in the Pharmaceuticals industry. TSND may be in some trouble as it scores bad on both profitability and health. TSND is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TSND had negative earnings in the past year.
In the past year TSND had a positive cash flow from operations.
In the past 5 years TSND reported 4 times negative net income.
In multiple years TSND reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -13.33%, TSND is in line with its industry, outperforming 40.63% of the companies in the same industry.
Looking at the Return On Equity, with a value of -64.65%, TSND is doing worse than 62.50% of the companies in the same industry.
TSND has a Return On Invested Capital of 4.28%. This is in the better half of the industry: TSND outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.33% | ||
| ROE | -64.65% | ||
| ROIC | 4.28% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TSND has a better Operating Margin (10.26%) than 84.38% of its industry peers.
TSND's Operating Margin has declined in the last couple of years.
TSND has a Gross Margin of 50.46%. This is in the better half of the industry: TSND outperforms 71.88% of its industry peers.
TSND's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.26% | ||
| PM (TTM) | N/A | ||
| GM | 50.46% |
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TSND is destroying value.
TSND has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TSND has been increased compared to 5 years ago.
The debt/assets ratio for TSND is higher compared to a year ago.
2.2 Solvency
TSND has an Altman-Z score of -0.87. This is a bad value and indicates that TSND is not financially healthy and even has some risk of bankruptcy.
TSND's Altman-Z score of -0.87 is in line compared to the rest of the industry. TSND outperforms 43.75% of its industry peers.
The Debt to FCF ratio of TSND is 18.35, which is on the high side as it means it would take TSND, 18.35 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 18.35, TSND is doing good in the industry, outperforming 71.88% of the companies in the same industry.
TSND has a Debt/Equity ratio of 1.77. This is a high value indicating a heavy dependency on external financing.
TSND has a Debt to Equity ratio of 1.77. This is amonst the worse of the industry: TSND underperforms 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.77 | ||
| Debt/FCF | 18.35 | ||
| Altman-Z | -0.87 |
ROIC/WACC0.47
WACC9.09%
2.3 Liquidity
A Current Ratio of 1.45 indicates that TSND should not have too much problems paying its short term obligations.
TSND has a worse Current ratio (1.45) than 62.50% of its industry peers.
A Quick Ratio of 1.07 indicates that TSND should not have too much problems paying its short term obligations.
TSND has a Quick ratio (1.07) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
TSND shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.29%.
TSND shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.80%.
Measured over the past years, TSND shows a very strong growth in Revenue. The Revenue has been growing by 36.80% on average per year.
EPS 1Y (TTM)-39.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-466.67%
Revenue 1Y (TTM)-14.8%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-16.15%
3.2 Future
TSND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.08% yearly.
The Revenue is expected to grow by 2.60% on average over the next years.
EPS Next Y47.11%
EPS Next 2Y32.69%
EPS Next 3Y22.74%
EPS Next 5Y13.08%
Revenue Next Year-13.74%
Revenue Next 2Y-4.82%
Revenue Next 3Y-0.88%
Revenue Next 5Y2.6%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TSND. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSND. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
75.00% of the companies in the same industry are more expensive than TSND, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, TSND is valued a bit cheaper than the industry average as 68.75% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.77 | ||
| EV/EBITDA | 10.16 |
4.3 Compensation for Growth
TSND's earnings are expected to grow with 22.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.69%
EPS Next 3Y22.74%
5. Dividend
5.1 Amount
TSND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TSND (10/15/2025, 7:00:00 PM)
1.25
+0.1 (+8.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners35.45%
Inst Owner ChangeN/A
Ins Owners5.91%
Ins Owner ChangeN/A
Market Cap462.18M
Analysts82.5
Price Target1.91 (52.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-317.53%
Min EPS beat(2)-614.39%
Max EPS beat(2)-20.66%
EPS beat(4)0
Avg EPS beat(4)-243.78%
Min EPS beat(4)-614.39%
Max EPS beat(4)-20.66%
EPS beat(8)0
Avg EPS beat(8)-269.57%
EPS beat(12)1
Avg EPS beat(12)-371.5%
EPS beat(16)3
Avg EPS beat(16)-184.77%
Revenue beat(2)0
Avg Revenue beat(2)-4.7%
Min Revenue beat(2)-6.15%
Max Revenue beat(2)-3.26%
Revenue beat(4)0
Avg Revenue beat(4)-4.36%
Min Revenue beat(4)-6.15%
Max Revenue beat(4)-2.6%
Revenue beat(8)1
Avg Revenue beat(8)-3.22%
Revenue beat(12)2
Avg Revenue beat(12)-3.34%
Revenue beat(16)2
Avg Revenue beat(16)-6.24%
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)28.55%
EPS NY rev (1m)-21.74%
EPS NY rev (3m)-37.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.16 | ||
| P/FCF | 28.77 | ||
| P/OCF | 14.7 | ||
| P/B | 2.79 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.16 |
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)0.04
FCFY3.48%
OCF(TTM)0.09
OCFY6.8%
SpS1.08
BVpS0.45
TBVpS-0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.33% | ||
| ROE | -64.65% | ||
| ROCE | 6.07% | ||
| ROIC | 4.28% | ||
| ROICexc | 4.54% | ||
| ROICexgc | 11.68% | ||
| OM | 10.26% | ||
| PM (TTM) | N/A | ||
| GM | 50.46% | ||
| FCFM | 4.02% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-2.11%
ROICexcg growth 5YN/A
ROICexc growth 3Y1.66%
ROICexc growth 5YN/A
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
F-Score4
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.77 | ||
| Debt/FCF | 18.35 | ||
| Debt/EBITDA | 4.25 | ||
| Cap/Depr | 54.65% | ||
| Cap/Sales | 3.85% | ||
| Interest Coverage | 1.19 | ||
| Cash Conversion | 45.49% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | -0.87 |
F-Score4
WACC9.09%
ROIC/WACC0.47
Cap/Depr(3y)90.87%
Cap/Depr(5y)192.32%
Cap/Sales(3y)7.77%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-466.67%
EPS Next Y47.11%
EPS Next 2Y32.69%
EPS Next 3Y22.74%
EPS Next 5Y13.08%
Revenue 1Y (TTM)-14.8%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-16.15%
Revenue Next Year-13.74%
Revenue Next 2Y-4.82%
Revenue Next 3Y-0.88%
Revenue Next 5Y2.6%
EBIT growth 1Y-37.21%
EBIT growth 3Y6.79%
EBIT growth 5YN/A
EBIT Next Year160.07%
EBIT Next 3Y44.3%
EBIT Next 5Y30.79%
FCF growth 1Y177.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.53%
OCF growth 3YN/A
OCF growth 5YN/A